Injective (INJ) climbed 7.61% on Saturday, reaching $3.24 as the token tested a historically significant support level. Trading volume rose 6.27% over the past Injective (INJ) climbed 7.61% on Saturday, reaching $3.24 as the token tested a historically significant support level. Trading volume rose 6.27% over the past

Injective Rebounds 8%, $3 Support Could Unlock $10 Upside

2026/02/07 13:00
3 min read

Injective (INJ) climbed 7.61% on Saturday, reaching $3.24 as the token tested a historically significant support level. Trading volume rose 6.27% over the past 24 hours to $105.31 million, reflecting renewed market interest amid broader cryptocurrency volatility.

Despite the daily rebound, INJ remains down 18.34% over the past seven days, underscoring the continued impact of macro crypto trends on its price.

Source: CoinMarketCap

Volatility Remains Elevated in INJ Market

In X post, Crypto analyst CryptoPulse noted that Injective has returned to a major long-term demand zone near the $3 mark following an extended price rally and subsequent sell-off.

Over the past three months, INJ surged sharply, peaking between $36 and $38 before encountering strong resistance, triggering aggressive profit-taking and a prolonged correction phase.

The resulting downtrend formed a pattern of lower highs and lower lows, signaling sustained bearish pressure. However, the recent stabilization near $3 suggests that buyers may be accumulating at this historically resilient level.

According to CryptoPulse, repeated defense of this zone could set the stage for a relief rally toward the $8–$10 range, provided bullish momentum continues to build.

Market data also points to elevated volatility, as long candle wicks indicate intense competition between buyers and sellers. While a short-term bounce is developing, analysts caution that a confirmed breakdown below $3 could expose INJ to deeper losses, reinforcing the importance of this support zone in determining near-term direction.

Source: X

Injective Implements IIP-617 Governance Update

Injective’s market structure has also been shaped by recent governance developments. On January 19, the community approved proposal IIP-617 with 99.89% voter support, introducing changes that accelerate the network’s transition toward a more deflationary supply model.

The update revises inflation parameters to reduce new token issuance more aggressively, while maintaining existing burn mechanisms. Since the network’s launch, approximately 6.85 million INJ have already been permanently removed from circulation.

These adjustments operate alongside the Injective Community BuyBack initiative, which uses ecosystem-generated revenue to repurchase and burn INJ tokens from the open market.

Rather than introducing new token management tools, the proposal strengthens existing mechanisms by embedding deflation directly into protocol-level economics. Injective’s core contributors describe the move as a long-term strategy to enhance scarcity and reinforce the network’s economic sustainability.

Despite structural improvements, INJ remains nearly 75% below its level from a year ago, highlighting the broader market’s cautious stance toward altcoins. Analysts note that while supply-side tightening may support long-term valuation, near-term price action remains heavily influenced by macro trends and Bitcoin market sentiment.

Also Read | Injective (INJ) Holds Critical $3 Support; Relief Rally Could Reach $10 Soon

Market Opportunity
Injective Logo
Injective Price(INJ)
$3.16
$3.16$3.16
-3.21%
USD
Injective (INJ) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.